2660 Patton Road
Roseville, MN 55113
Rebiotix Inc., a subsidiary of the Ferring Pharmaceuticals Group, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome. It is increasingly recognized that restoration of a healthy gut microbiota is necessary for the effective treatment of a large number of challenging diseases. Rebiotix is addressing this need through our Microbiota Restoration Therapy™ drug platform, which delivers live, human-derived microbes into a sick patient’s intestinal tract to treat disease. We have the most advanced human clinical program evaluating a microbiota-based drug conducted in coordination with a regulatory authority.
Rebiotix has conducted three clinical trials of our lead Microbiota Restoration Therapy™ drug platform RBX2660 for the prevention of recurrent Clostridium difficile (C. diff) infections, and we are currently enrolling in a Phase 3 clinical trial, in conjunction with the U.S Food and Drug Administration under an Independent New Drug Application. We are also supporting investigator-sponsored trials of RBX2660 for indications in gastroenterology, infectious diseases, and hepatology.
Rebiotix has also supported a first-in-human investigator-sponsored trial of RBX7455, a lyophilized room-temperature-stable oral capsule formulation of Rebiotix’s MRT, for the prevention of recurrent Clostridium difficile infections. This trial has completed enrollment, with clinical and microbiome outcomes to be reported in October 2018.
Rebiotix has also developed a Microbiome Health Index™ (MHI) to provide the microbiome research community with a standardized metric to quantify rehabilitation of the human microbiome. The MHI has shown to be highly correlated with and predictive of clinical outcomes in trials of RBX2660 and RBX7455 for recurrent Clostridium difficile infections.